Írland - enska - HPRA (Health Products Regulatory Authority)

parallel lines ltd - capsule - 10 milligram

Írland - enska - HPRA (Health Products Regulatory Authority)

pco manufacturing - nifedipine - capsule - 5 milligram

Írland - enska - HPRA (Health Products Regulatory Authority)

pco manufacturing - nifedipine - capsule - 10 milligram

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - nifedipine -

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - nifedipine -

Nýja-Sjáland - enska - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - amlodipine besilate 6.934mg equivalent to amlodipine 5 mg - tablet - 5 mg - active: amlodipine besilate 6.934mg equivalent to amlodipine 5 mg excipient: colloidal silicon dioxide magnesium stearate mannitol microcrystalline cellulose sodium starch glycolate - indicated for the first line treatment of hypertension and can be used as the sole agent to control blood pressure in the majority of patients. patients not adequately controlled on a single antihypertensive agent may benefit from the addition of ozlodip, which has been used in combination with a thiazide diuretic, beta adrenoceptor blocking agent, or an angiotensinconverting enzyme inhibitor.

Nýja-Sjáland - enska - Medsafe (Medicines Safety Authority)

bayer new zealand limited - nifedipine 20mg (plus 10% overage) - modified release tablet - 20 mg - active: nifedipine 20mg (plus 10% overage) excipient: cellulose acetate hypromellose   iron oxide red macrogol 3350 magnesium stearate opacode black s-1-17823 opadry pink oy-s-24914 polyethylene oxide sodium chloride - treatment of coronary heart disease

Nýja-Sjáland - enska - Medsafe (Medicines Safety Authority)

bayer new zealand limited - nifedipine 33mg (active blend) - modified release tablet - 30 mg - active: nifedipine 33mg (active blend) excipient: cellulose acetate hypromellose   iron oxide red macrogol 3350 magnesium stearate as 0.4mg in active blend, 0.2mg in osmotic blend opacode black s-1-17823 opadry pink oy-s-24914 polyethylene oxide sodium chloride - treatment of coronary heart disease

Nýja-Sjáland - enska - Medsafe (Medicines Safety Authority)

bayer new zealand limited - nifedipine 66mg (active blend) - modified release tablet - 60 mg - active: nifedipine 66mg (active blend) excipient: cellulose acetate hypromellose   iron oxide red macrogol 3350 magnesium stearate as 0.8mg in active blend, 0.4mg in osmotic blend opacode black s-1-17823 opadry pink oy-s-24914 polyethylene oxide sodium chloride - -treatment of coronary heart disease -chronic stable angina pectoris (angina of effort) - treatment of hypertension

Nýja-Sjáland - enska - Medsafe (Medicines Safety Authority)

bayer new zealand limited - nifedipine 90mg - modified release tablet - 90 mg - active: nifedipine 90mg excipient: cellulose acetate hyprolose hypromellose   iron oxide red   macrogol 3350 magnesium stearate polyethylene oxide propylene glycol sodium chloride titanium dioxide